Please login to the form below

Not currently logged in
Email:
Password:

S-A takeover approach rejected

Sanofi-aventis' suspected takeover approach for Genzyme has been rejected, according to two sources

Sanofi-aventis' (S-A) suspected takeover approach for Genzyme has been rejected, according to two sources.

Analysts have speculated that Genzyme, one of the world's leading biotechnology companies, could command at least $22bn, or $80 a share – a 48 per cent profit over Genzyme's closing price the day before S-A made its approach. It is thought that investors will insist on at least $20bn in a sale.

Genzyme could accrue an annual revenue of $6.6bn by 2013 if it resolves manufacturing defects that resulted in the figure dropping to $4.5bn in 2009.

GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) have also been rumoured to be bidding for Genzyme.

S-A and Genzyme have refused to comment on the claims.

27th July 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Stick or Twist? Healthcare brands in a (post) COVID-19 world
...